Transition metal chelators and ionophores have shown promise as alternative chemotherapeutic strategies by selectively altering the concentrations of iron, copper, and zinc in cancer cells.

An increased demand for iron is a hallmark of cancer cells and is thought necessary to promote high cell proliferation, tumor progression and metastasis. This makes iron metabolism an attractive therapeutic target. Unfortunately, current iron-based therapeutic strategies often lack effectiveness and can elicit off-target toxicities. We report here a dual-therapeutic prodrug, DOXjade, that allows for iron chelation chemo-photothermal cancer therapy. This prodrug takes advantage of the clinically approved iron chelator deferasirox (ExJade®) and the topoisomerase 2 inhibitor, doxorubicin (DOX). Loading DOXjade onto ultrathin 2D Ti₃C₂ MXene nanosheets produces a construct, Ti₃C₂-PVP@DOXjade, that allows the iron chelation and chemotherapeutic functions of DOXjade to be photo-activated at the tumor sites, while potentiating a robust photothermal effect with photothermal conversion efficiencies of up to 40%. Antitumor mechanistic investigations reveal that upon activation, Ti₃C₂-PVP@DOXjade serves to promote apoptotic cell death and downregulate the iron depletion-induced iron transferrin receptor (TfR). A tumor pH-responsive iron chelation/photothermal/chemotherapy antitumor effect was achieved both in vitro and in vivo. The results of this study highlight what may constitute a promising iron chelation-based phototherapeutic approach to cancer therapy.

Clinical imaging techniques are widely used to detect, locate, and track the growth or shrinkage of cancerous tumors. Although these techniques have shown impressive results, they often come with health risks due to the use of toxic contrast agents or ionizing radiation. To address these limitations, research efforts have been focused on the development of new imaging techniques. Among the emerging medicinal methods, photoacoustic imaging is receiving much attention. This method effectively combines the most important benefits of both ultrasound and fluorescence imaging, while minimizing their respective drawbacks via a light‐in and ultrasound‐out approach. This review article focuses on the fundamental concept, recent advances, and strategies for novel contrast agents based on molecular metal complexes or metallic nanoparticles for use in photoacoustic imaging.

We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells.